Becoming All Of Our Selves with Dr. Paula O'Connor, Part II

3 Black Docs

Conteúdo fornecido por Winkz Productions, Dr. Karen Winkfield, Dr. Zanetta Lamar, and Dr. Tiffany Avery. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Winkz Productions, Dr. Karen Winkfield, Dr. Zanetta Lamar, and Dr. Tiffany Avery ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.

3+ y ago 36:47

MP3•Home de episódios

We are continuing our conversation with Dr. Paula O'Connor and delving into the role of pharma in access to medicine and clinical trials. Dr. O'Connor goes over the safety measures in place to keep patients safe throughout a trial and how clinical trials can give access to novel drugs to patients who may not otherwise be able to afford them.

About Dr. Paula O'Connor

Dr. O'Connor is a hematologist oncologist with over 15 years of experience in biotech and drug development leading Clinical Development, Medical Affairs functions, managing people and teams, while helping to bring multiple products to the market.

Most recently, Dr. O'Connor led the US Medical Affairs function at Oncopeptides, Inc., helping them to commercialize their first product, a peptide drug conjugate. Earlier in her career, Dr. O'Connor led programs for novel biologics (Rituxan, Avastin), small molecules (Tarceva, Nexavar, rociletinib, Rubraca, and Talzenna), and biosimilars (Udenyca).

Paula served as the Executive Vice President of Clinical Development at Coherus Biosciences; the Global Development Lead for Talzenna at Medivation through its acquisition by Pfizer; the Medical Affairs Lead for Rubraca and rociletinib at Clovis Oncology; the Joint Global Development Lead for Nexavar and Global Development Lead for Oprozomib at Onyx Pharmaceuticals through its acquisition by Amgen; and in roles of increasing responsibility at Genentech, Inc. through its acquisition by Roche.

Paula obtained her medical degree from Stanford University; did her Medical residency at Massachusetts General Hospital, where she was the first African American Chief Resident in Internal Medicine; and did her Hematology-Oncology fellowship at the MGH/BWH/DFCI combined program.

Outside of work, Paula is a parent, a tennis fan, and the owner of 2 burmese cats.

New Episodes every Tuesday, available wherever you get your podcasts!

Rate and Subscribe! Also, join us for our live streams on Facebook and Youtube!

A special thanks to our sponsor, Oncopeptides. Oncopeptides is a rapidly growing biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is science driven and committed to bringing innovation to patients with an unmet medical need and improving patient lives. Oncopeptides is committed to the diversity of Multiple Myeloma patients and doing their part to eradicate health disparities in African American patients.

Learn more about Oncopeptides at https://www.oncopeptides.com/en

Join the Conversation! Follow us on social media!

3 Black Docs

facebook.com/3blackdocs
twitter.com/3blackdocs
instagram.com/3blackdocs
YouTube.com/3blackdocs

Dr. Karen Winkfield

facebook.com/drwinkfield
twitter.com/drwinkfield
instagram.com/drwinkfield

Dr. Zanetta Lamar

facebook.com/drzanetta
instagram.com/drzanetta

94 episódios